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Introduction
Hematopoietic stem cell transplantation (HSCT) is a medical procedure used to
treat malignant and non-malignant diseases of the blood, as well as solid tumors.
The outcome of HSCT is influenced both by clinical and genetic factors.
Compatibility between the recipient and the donor in terms of HLA is a well-
known limiting factor for the success of allogeneic HSCT.1 In addition, genes other
than those of the HLA system, in particular those that are highly polymorphic, have
been proposed as potential factors affecting the success of this therapy.2
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Transforming growth factor β-1, encoded by the TGFB1 gene, is acytokine that plays a central role in many physiological and patho-genic processes. We have sequenced TGFB1 regulatory region and
assigned allelic genotypes in a large cohort of hematopoietic stem cell trans-
plantation patients and donors. In this study, we analyzed 522 unrelated
donor-patient pairs and examined the combined effect of all the common
polymorphisms in this genomic region. In univariate analysis, we found
that patients carrying a specific allele, ‘p001’, showed significantly reduced
overall survival (5-year overall survival 30.7% for p001/p001 patients vs.
41.6% others; P=0.032) and increased non-relapse mortality (1-year non-
relapse mortality: 39.0% vs. 25.4%; P=0.039) after transplantation. In mul-
tivariate analysis, the presence of a p001/p001 genotype in patients was
confirmed as an independent factor for reduced overall survival [hazard
ratio=1.53 (1.04-2.24); P=0.031], and increased non-relapse mortality [haz-
ard ratio=1.73 (1.06-2.83); P=0.030]. In functional experiments we found a
trend towards a higher percentage of surface transforming growth factor β-
1-positive regulatory T cells after activation when the cells had a p001 allele
(P=0.07). Higher or lower production of transforming growth factor β-1 in
the inflammatory context of hematopoietic stem cell transplantation may
influence the development of complications in these patients. Findings indi-
cate that TGFB1 genotype could potentially be of use as a prognostic factor
in hematopoietic stem cell transplantation risk assessment algorithms.
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ABSTRACT
One of the genes that are likely to play an important role
in the outcome of allogeneic HSCT is TGFB1, which
encodes transforming growth factor-β1 (TGF-β1). TGF-β1
is a cytokine that plays a central role in many physiologi-
cal and pathogenic processes, having pleiotropic effects on
cell proliferation, differentiation, migration and survival,
as well as being a fundamental component of the immune
system. TGF-β1 is likely to be relevant for both therapeu-
tic and pathogenic immune processes associated with the
different stages of HSCT.3 Genetic variation resulting in
differences in its production and/or function could play a
role in the way that this cytokine modifies these immune
processes.
Regulatory activity for this gene, located at chromo-
some 19q13.1-q13.3, has been mapped to approximately
3.0 kilobases (kb) from positions -2665 to +423 in its exon
1 (+1 being the translation start site). This region includes
two promoter sites, two negative regulatory elements and
two enhancers lying upstream of the first promoter.4
Several polymorphisms in TGFB1 regulatory region
have been identified, and these are known to cause alter-
ations in cytokine secretion in several settings.4 Previous
work allowed for the definition of 17 TGFB1 regulatory
region and exon 1 alleles, which are formed by the combi-
nation of 18 SNPs and other kinds of variation (Online
Supplementary Table S1).4,5 We have recently expanded this
inventory of TGFB1 alleles with the discovery of other less
common variant combinations.6
The role of polymorphism in TGFB1 in the outcome of
HSCT has been examined in some studies.7 However, the
results have not been consistent. In this study, we aimed
at comprehensively analyzing the role of genetic variation
in TGFB1 regulatory region and exon 1 in a large cohort of
UD-HSCT recipients and donors. In addition, since regu-
latory T cells (Treg) are major producers of TGF-β1 and
have the unique ability of expressing its latent form on
their surface upon stimulation,8 as well as being likely
effectors or targets during the immunological events tak-
ing place prior, during and after HSCT, we have performed
functional assays to further understand the effect of this
variation on the way that TGF-β1 is expressed by human
regulatory Treg. 
Methods
Patients, donors, and clinical data
Hematopoietic stem cell transplantation patient and donor sam-
ples are part of the Anthony Nolan Research Institute’s stem cell
transplantation sample repository (www.myresearchproject.org.uk,
application number MREC 01/8/31).
Healthy volunteer donors were used to obtain mononuclear
cells for functional experiments.  Patients’ clinical data were col-
lected by the Anthony Nolan Research Institute in collaboration
with the British Society for Blood and Marrow Transplantation. 
All samples were collected according to the Anthony Nolan
Research Institute’s review board-approved guidelines and written
informed consent was obtained from all participants. 
Sequencing of the regulatory region of TGFB1
The 3.0 kb upstream regulatory region of TGFB1 was analyzed
for polymorphism by Sanger sequencing, as explained elsewhere.6
Briefly, based on the studies by Shah et al.,4,5 the region extending
from -2,664 to +423 according to this gene’s translation start site
was sequenced and the sequenced fragments were then analyzed,
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Table 1. Patients’, donor and transplant characteristics in the
hematopoietic stem cell transplantation cohort (n=504*).
                                                              N                         %
Patient age (years)                                                                           
Median 27.9 (range 0.4-63.8)                        
0-20                                                                176                           34.9
20-40                                                              201                           39.9
40-60                                                              126                           25.0
>60                                                                  1                              0.2
Donor age (years)                                           
Median 35.0 (range 19.2-60.4)
0-20                                                                  2                              0.4
20-40                                                              369                           73.2
40-60                                                              132                           26.2
>60                                                                   1                              0.2
Sex (male)                                                        
Patients                                                         322                           63.9
Donors                                                          382                           75.8
Sex matching                                                    
Patient-donor                                                 
Male-male                                                    256                           50.8
Male-female                                                 66                            13.1
Female-female                                             56                            11.1
Female-male                                               126                           25.0
HLA-matching                                                   
10/10 matched                                             358                           71.0
1 mismatch                                                  100                           19.8
>1 mismatch                                                46                             9.1
Disease                                                              
AML                                                                136                           27.0
ALL                                                                 155                           30.8
CML                                                               111                           22.0
MDS                                                                45                             8.9
Other1                                                            57                            11.3
Disease status                                                  
Complete remission/chronic phase      417                           82.7
Other                                                              77                            15.3
Unknown                                                       10                             2.0
CMV status                                                        
Patient(+)-donor(+)                                64                            12.7
Patient(+)-donor(-)                                  88                            17.4
Patient(-)-donor(+)                                  51                            10.1
Patient(-)-donor(-)                                   282                           56.0
Unknown                                                       19                             3.8
TBI                                                                       
Yes                                                                 434                           86.1
No                                                                    55                            10.9
Unknown                                                       15                             3.0
SC source                                                          
BM                                                                  340                           67.5
PB                                                                   159                           31.5
Both                                                                 2                              0.4
Unknown                                                        3                              0.6
T-cell depletion                                                
Yes                                                                 427                           84.7
No                                                                    22                             4.4
Unknown                                                       55                            10.9
GvHD prophylaxis                                                                              
None                                                                4                              0.8
Cyclosporin                                                  131                           26.0
Cyclosporin+MTX                                      329                           65.3
Other                                                              28                             5.6
Unknown                                                       12                             2.4
Transplant year                                                 
1996-2001                                                      253                           50.2
2002-2009                                                      251                           49.8
1Includes secondary acute leukemia, non-Hodgkin lymphoma, primary immune defi-
ciency, bone marrow failure, multiple myeloma, metabolic disease, myeloproliferative
neoplasia, biphenotypic acute leukemia, Hodgkin disease, undifferentiated acute
leukemia. *18 pairs out of 522 eligible lacked clinical data. AML: acute myeloid
leukemia; ALL: acute lymphoid leukemia; CML: chronic myeloid leukemia; BM: bone
marrow; CMV: cytomegalovirus; GvHD: graft- versus-host disease; HLA: human leuko-
cyte antigen; MDS: myelodysplastic syndrome; MTX: methotrexate; PB: peripheral
blood; SC: stem cell; TBI: total body irradiation. 
and used to assign a TGFB1 regulatory region and exon 1 allelic
genotype4,5 based on the genotypes for 18 known polymorphic
positions. In cases where there were theoretical ambiguities, the
phase of the relevant polymorphic positions was defined by allele-
specific amplification strategies using different primer combina-
tions.6
Cellular assays
CD4+CD25– and CD4+CD25+ cells were isolated from peripher-
al blood mononuclear cells (PBMC) with a human CD4+CD25+
Regulatory T-Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany).
Isolated cell fractions were stained with antibodies against CD4
(PerCP, clone SK3, BD Biosciences, Oxford, UK; APC, clone RPA-
T4, eBioscience, San Diego, USA), CD127 (FITC, clone eBioRDR5,
eBioscience; PerCP, clone eBioRDR5, eBioscience, San Diego,
USA), and CD25 (APC, clone 2A3, BD Biosciences, Oxford, UK;
PerCP-Cy5.5, clone BC96, BioLegend, San Diego, USA). Surface
TGF-β1 expression on isolated Treg was assessed by staining of its
latency-associated peptide (αLAP-PE, clone 27232, R&D Systems,
Abingdon, UK) on resting and activated CD4+CD25+CD127lo
cells. 
The cells were activated with antibodies against CD3 and CD28
(NA/LE mouse, clones HIT3a and CD28.2, respectively, BD
Biosciences, Oxford, UK) at 10 mg/mL. Non-stimulated and plate-
bound antibody-stimulated cells were used as controls. 
Statistical analysis
The Z-test was used to compare TGFB1 regulatory region and
exon 1 allele variant and genotype frequencies between the HSCT
patient and donor cohorts (Online Supplementary Table S2).
Deviation from Hardy-Weinberg equilibrium was assessed with
Fisher’s exact test or χ2 test (Online Supplementary Tables S3 and S4).
Detailed information on SNP and allele frequencies and the assign-
ment of TGFB1 regulatory region and exon 1 genotypes is avail-
able in the Online Supplementary Appendix.
The main clinical end point was overall survival (OS).
Secondary end points were event-free survival (EFS), non-relapse
mortality (NRM), acute graft-versus-host disease (aGvHD) (grades
I-IV, II-IV or III-IV), and relapse. EFS was defined as survival with-
out relapse (an event was death of any cause or relapse). For uni-
variate analysis of time-to-event data (OS, EFS), the Kaplan-Meier
method was used. Log rank statistics were used to compare OS
and EFS probabilities between groups of interest. The probabilities
of NRM and relapse were estimated by the cumulative incidence
method, and compared using Gray’s test, with relapse and death
without relapse as competing events, respectively. aGvHD fre-
quencies were compared by means of the χ2 test, or by Fisher’s
exact test.
Multivariate analyses were performed using Cox’s regression
(OS, EFS), the Fine-Gray method (NRM, relapse), or logistic regres-
sion (aGvHD) as appropriate. Clinical variables with P≤0.2 in uni-
variate models for association with transplant outcome were
selected for multivariate analyses.
Kruskal-Wallis and Mann-Whitney tests were used to compare
Treg LAP expression levels between TGFB1 regulatory region and
exon 1 genotype groups. 
Results
Cohort
The cohort was composed of 522 unrelated myeloabla-
tive transplants performed between 1996 and 2009.
Typing was possible for only patient or donor DNA for 9
and 11 pairs, respectively. Although permission for genetic
testing was granted, permission for use of clinical data was
not granted in 18 cases [patient TGFB1 genotypes:
p001/p003 (n=7), p003/p003 (n=6), p001/p001 (n=2),
p006/p014 (n=2), and p014/p014 (n=1)] and these were
thus excluded. Consequently, when clinical data were
analyzed, the final number of pairs included for patient
and donor genotypes were 493 and 495, respectively
(‘whole cohort’). The characteristics of the patients, their
donors and the transplants are presented in Table 1. T-cell
depletion with alemtuzumab was used in 85% of the
patients. 
Descriptive results for the typing of TGFB1 regulatory
region and exon 1 alleles in the patient-donor cohort  
Only six of the previously reported alleles were seen in
the cohort: p001, p003, p006, p009, p013, and p014, four
of which were predominant (Table 2). Online
Supplementary Table S5 shows the genotype frequencies
observed. Neither the allele nor the genotype frequencies
differed significantly between patients and donors (Z test;
P>0.050). 
Nine samples (5 donors and 4 patients) showed geno-
types that did not correspond with any allelic combination
based on the previously known 17 TGFB1 regulatory
region and exon 1 alleles. These samples were shown to
carry a combination of a known allele and a novel allele.6
Survival analysis
Median follow up in the cohort was 20.5 months (range
0.2-178.9 months). Five-year OS and EFS in the whole
cohort were 40.9% (95%CI: 36.6%-45.2%) and 30.4%
(95%CI: 26.3%-34.5%), respectively. Median OS was
E. Arrieta-Bolaños et al.
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Table 2. TGFB1 regulatory region and exon 1 allele frequencies found in the UD-HSCT patient-donor cohort.
Allele Patients Donors
Frequency Copies Carriers Carrier Frequency Copies Carriers Carrier Z P
frequency frequency
p001 0.3004 307 264 0.5166 0.2865 294 256 0.4990 0.7 0.49
p003 0.5411 553 415 0.8121 0.5331 547 405 0.7895 0.4 0.72
p006 0.0753 77 73 0.1429 0.0867 89 88 0.1715 0.9 0.34
p009 0.0000 0 0 0.0000 0.0010 1 1 0.0019 N/A N/A
p013 0.0020 2 2 0.0039 0.0000 0 0 0.0000 N/A N/A
p014 0.0773 79 75 0.1468 0.0877 90 87 0.1696 0.9 0.39
Total 0.9961 1018 0.9951 1021
21.6 months (95%CI: 11.5-31.6 months). Median EFS was
9.9 months (95%CI: 7.6-12.2 months). One-year cumula-
tive incidence for NRM was 26.8% in the whole cohort.
Five-year relapse cumulative incidence was 39.0%.
Median time to relapse was 51.6 months (95%CI: 9.5-93.8
months).
The effect of TGFB1 polymorphism on survival was
assessed in three models: recessive allelic, dominant allel-
ic, and SNP (-1347C>T)-associated effects. Both the effect
of donor and patient-borne polymorphism was independ-
ently assessed. 
Recessive models 
Variation in patient TGFB1 regulatory region and exon 1
had a significant effect on the OS of the whole cohort.
When homozygosity for alleles p001 and p003 and het-
erozygosity were compared (Figure 1A), significant differ-
ences were found (n=486 when excluding patients
homozygous for p006 and p014 due to low numbers;
P=0.041). Patients homozygous for p003 (n=132) had the
highest median OS (43.8 months), while patients
homozygous for the p001 allele (n=41) had the lowest (7.9
months). When pairwise comparisons were considered,
there was a significant difference between patients
homozygous for p001 and p003 (P=0.014), and a trend
between p001 and the heterozygous group (n=313;
P=0.071). Patients with a p001/p001 genotype (n=41)
show significantly lower OS than the rest of the patients
of any other genotype (n=452; 5-year OS 30.7% for
p001/p001 patients vs. 41.6% others; P=0.032) (Figure 1B). 
No differences in OS according to donor allele were
found (n=491; P=0.47). Other TGFB1 alleles could not be
tested due to low numbers of homozygotes. Among all
patient genotypes with n>20, only p001/p001 shows a sig-
nificant effect on OS in the whole cohort when compared
to the rest of the genotypes (data not shown).
Dominant models
No effect of patient alleles was seen using this model
(Figure 1C for p001). However, patients whose donors car-
ried at least one copy of p001 had worse OS than patients
whose donor lacked this allele (median OS 13.7 vs. 39.5
months, respectively; P=0.043). Alleles p003, p006 and
p014 did not have statistically significant dominant donor
effects on OS in this cohort.
TGFB1 -1347C>T (rs1800469) 
The -1347T variant was close to a marker for allele p001
in this cohort (41/43 TGFB1 -1347TT patients were
p001/p001). There was no statistical evidence for a reces-
sive effect of either patient (n=493; P=0.11) or donor
(n=495; P=0.11) genotype on OS (Figure 2A). When the
dominant model for -1347C was tested (i.e. TT vs.
CT+CC) (Figure 2B), patients that had the -1347TT geno-
type (n=43) had significantly lower OS than that of
patients bearing at least one C variant (median OS 7.9 vs.
25.1 months; P=0.036). No evidence of a donor genotype
effect on OS was found in this model (P=0.82) (Figure 2C). 
Analysis of EFS, NRM, relapse and aGvHD
There was a significant increase in the incidence of
NRM among patients that bear the p001 allele (1-year
NRM: 39.0%; P=0.039) or the -1347T (1-year NRM:
39.5%; P=0.029) in a homozygous manner when com-
pared to other genotypes (1-year NRM: 25.4% and 25.3%,
TGFB1 polymorphism reduces survival after HSCT
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Figure 1. Survival analysis according to the effects of patient TGFB1
regulatory region and exon 1 allele for the whole cohort. (A) Patients
homozygous for allele p001 (n=41) show significantly worse overall
survival (OS) when compared to patients homozygous for p003
(n=132; P=0.014). A trend for lower OS in patients homozygous for
p001 was also found when compared to heterozygous patients
(n=309; P=0.071). (B) Patients homozygous for TGFB1 allele p001
(n=41) show reduced OS when compared with all other genotypes
(n=452; P=0.032). (C) Patients with at least one copy of TGFB1 allele
p001 (n=255) do not show significantly different OS from patients
with other genotypes (n=238; P=0.37).
A
B
C
respectively) (Figure 3A-C). There was no effect of the
dominant presence of p001 among donors (Figure 3D). 
None of the models tested impacted on EFS, disease
relapse or aGvHD (grades I-IV, II-IV or III-IV).
Multivariate analyses
Based on the univariate analyses for the clinical factors
(Table 3), patient age, donor age, patient sex, HLA match-
ing, disease status, cytomegalovirus (CMV) matching, and
use of total body irradiation (TBI) were selected for inclu-
sion in the multivariate model for OS. Likewise, patient
age, HLA matching, CMV matching, use of TBI, and use
of T-cell depletion were selected for the NRM model.
For OS, disease status at transplant and patient age
together with the recessive allelic model were significant
factors associated with this outcome (Table 4). When the
-1347C dominant and the ‘p001/p001 versus other geno-
type’ models were examined, both were found to be sig-
nificantly associated with OS together with patient age,
HLA matching, and disease status. Overall, patients older
than 40 years of age, not transplanted in complete remis-
sion/chronic phase nor from 10/10 HLA-matched donors,
and being homozygous for TGFB1 p001 (or -1347T) were
associated with decreased OS.
E. Arrieta-Bolaños et al.
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Table 3. Analysis of the univariate association between clinical factors and overall survival and non-relapse mortality in the whole cohort (n=504). 
Risk factor Median OS (months) P NRM P
(cumulative incidence)3
Patient age 
> 40 years 7.6 <0.001 36.2 0.002
< 40 years 40.4 23.6
Donor age 
> 30 years 17.0 0.081 28.8 0.38
< 30 years 45.0 21.3
Sex 
Female patients 40.5 0.15 24.7 0.37
Male patients 17.0 28.0
Female donors 34.0 0.32 27.9 0.98
Male donors 18.7 26.4
Sex matching
Overall matched 22.4 0.84 26.9 0.72
Overall mismatched 21.3 26.6
Female to male 12.5 0.59 30.3 0.69
Other 22.4 26.2
HLA-matching
0 mismatches 28.6 0.051 23.7 0.048
1 mismatch 11.3 31.0
>1 mismatch 8.6 41.3
Disease status
Low risk1 26.4 0.004 26.4 0.44
High risk 7.6 32.5
CMV status
Matched2 27.2 0.035 24.0 0.012
Not matched 12.2 35.5
TBI presence
Yes 18.7 0.089 27.9 0.080
No N/A 18.1
SC source
BM 19.5 0.66 29.4 0.24
PB 27.8 21.4
T-cell depletion
Yes 22.1 0.95 27.4 0.18
No 14.4 13.6
GvHD prophylaxis
None 7.8 0.23 N/A 0.74
Cyclosporin 19.1 26.7
Cyclosporin+MTX 25.7 26.4
Other 8.9 28.6
Unknown 7.9 33.3
Transplant year
1996-2001 14.4 0.23 29.6 0.36
2002-2009 32.1 23.9
1Complete remission/chronic phase; 2cytomegalovirus (CMV) matching: CMV positive-CMV positive; CMV negative-CMV negative; 31-year NRM cumulative incidence. BM: bone mar-
row; GvHD: graft-versus-host disease; HLA: human leukocyte antigen; MTX: methotrexate; NRM: non-relapse mortality; OS: overall survival; PB: peripheral blood; SC: stem cell; TBI:
total body irradiation.
For NRM, patient homozygosity for TGFB1 p001 (or -
1347T), patient age older than 40 years, and the presence
of one or more allelic HLA mismatches (i.e. ≤9/10) were
associated with increased probability of death (Table 4).  
Functional consequences of TGFB1 regulatory region
and exon 1 alleles in Treg
When Treg from healthy donors were stimulated with
antibodies against CD3 and CD28, an upregulation of sur-
face LAP, which peaked at 24 h of culture, was detected.
This upregulation was observed only on the CD4+,
CD127lo cells and CD25+ cells, as previously described.8
As shown in Figure 4, TGFB1 genotype appears to influ-
ence the levels of LAP expressed by Treg upon TCR stim-
ulation. A trend towards higher LAP+ levels was seen
when the sample expressed a p001 allele (Mann-Whitney
test; P=0.07). An analysis of p001/p001 individuals on
their own was not possible because of the reduced fre-
quency of this genotype among available healthy volun-
teer donors. 
Discussion 
The present study revealed that homozygosity for a
TGFB1 p001 allele in UD-HSCT patients was associated
with significantly worse OS and NRM. Cellular experi-
ments suggest a potential functional effect of TGFB1 p001,
as there was a trend toward higher expression of surface
TGF-β1 on in vitro stimulated Treg that bore this allele.
This study is the largest performed so far on the role of
TGFB1 polymorphisms in HSCT. In contrast to previous
studies, the analysis encompassed the combined effect of
various polymorphisms organized in defined alleles in a
genomic region of approximately 3 kb. 
A few studies have analyzed TGFB1 polymorphism in
HSCT, but their heterogeneity makes comparisons diffi-
cult.7 Most previous studies are small (54% included less
than 100 pairs) or have investigated rare alleles. Moreover,
most of the studies have focused their analysis on one or
two SNPs and only on their impact on GvHD. Two early
studies also used pre-existing classifications of the geno-
types in “high producer” and “low producer” groups,
potentially introducing a bias in their analyses.9-11
Studies in mostly related donor cohorts have found no
association for TGFB1 +29T>C and +74G>C or their com-
bined +29~+74 genotypes with OS, GvHD, engraftment or
infections.9,12 In a larger study with mismatched UD-HSCT,
there was no consistent association of TGFB1 -1347C>T
with OS, engraftment or GvHD, despite initial findings in a
discovery cohort.13 Finally, in two recent reports analyzing
relatively large cohorts of mostly related donor transplants,
TGFB1 -1347 TT and CT patients showed increased inci-
dence of aGvHD, but no effect on OS, EFS, or NRM.14,15
TGFB1 -1347T was found to be a risk factor for skin
aGvHD but protective against lung cGvHD.15 
In our analyses, there was no statistical confirmation of a
role of +29T>C16 (data not shown). An explanation for this
difference could be the fact that +29CC genotypes could
include both p001 and p014.4 The presence of p014 could
not be analyzed for a recessive effect in our cohort.
However, since OS in +29CC patients was not statistically
different from +29TT and TC individuals, this could sug-
gest the lack of effect from p014. Interestingly, a study per-
formed in Chinese HSCT patients (n=240) found lower
TGFB1 polymorphism reduces survival after HSCT
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Figure 2. Survival analysis according to the effects of patient TGFB1
-1347C>T for the whole cohort. (A) Among the whole cohort (n=493),
patients bearing a -1347TT genotype (n=43) show a trend toward
lower OS (P=0.11) when compared to other genotypes. When pairwise
comparisons are made, patients with a -1347TT genotype (n=43)
have significantly lower OS than patients with -1347CC (n=237;
P=0.039). In a dominant model for the C variant, (B) the presence of
a TGFB1 -1347TT in patients results in significantly lower overall sur-
vival (OS) [(median OS TT (n=43) vs. CC+CT (n=450) 7.9 vs. 25.1
months; P=0.036)]. (C) No effect of the donor genotype (TT, n=35;
CC+CT, n=460) was suggested by this dominant model (P=0.82).
A
B
C
incidence of aGvHD in patients whose donors were TGFB1
-1347TT individuals, and also in patients who bore at least
one copy of the T variant, but with no effect on OS, NRM
or relapse.17 However, it is uncertain if TGFB1 -1347T corre-
lates with allele p001 in the Chinese population.
In the present study, the effect seen for allele p001 on
OS and NRM could not be explained by increases in the
incidence of aGvHD. This might be due to the fact that
most of the transplants included in our cohort were T-cell
depleted, and the incidence of aGvHD was low. Despite
this, there remains the possibility that this cytokine could
modify this complication, for example, by affecting the
generation of Th17 cells.18 Alternatively, the genetic asso-
ciation with NRM could potentially be explained by
E. Arrieta-Bolaños et al.
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Table 4. Analysis of the multivariate association between clinical factors and TGFB1 regulatory region and exon 1 polymorphism and their effect
on overall survival and non-relapse mortality in the whole cohort. 
Outcome Model Factor1 HR [95%CI] P
OS Recessive allelic (n=476) Patient p001/p001 vs. heterozygous 1.38 [0.94-2.04] 0.103
Patient p003/p003 vs. heterozygous 0.78 [0.59-1.02] 0.065
Patient age < 40 vs. > 40 0.61 [0.47-0.78] <0.001
Disease status (low risk vs. high risk) 0.72 [0.53-0.97] 0.032
Dominant -1347C (n=483) Patient -1347 TT vs. CC+CT 1.52 [1.04-2.21] 0.031
Patient age < 40 vs. > 40 0.59 [0.46-0.76] <0.001
Disease status (low risk vs. high risk) 0.73 [0.54-0.98] 0.038
HLA matched 10/10  vs. ≤ 9/10 0.77 [0.60-0.98] 0.034
p001/p001 vs. other genotypes Patient p001/p001 vs. other 1.53 [1.04-2.24] 0.031
(n=483) Patient age < 40 vs. > 40 0.59 [0.46-0.76] <0.001
Disease status (low risk vs. high risk) 0.73 [0.54-0.98] 0.039
HLA matched 10/10 vs. ≤ 9/10 0.77 [0.61-0.98] 0.035
NRM Recessive allelic (n=486) Patient p001/p001 vs. heterozygous 1.80 [1.08-3.00] 0.024
Patient p003/p003 vs. heterozygous 1.11 [0.76-1.60] 0.580
HLA matched 10/10 vs. ≤ 9/10 0.73 [0.52-1.01] 0.065
Patient age < 40 vs. > 40 0.60 [0.43-0.84] 0.003
Dominant -1347C (n=493) Patient -1347 TT vs. CC+CT 1.79 [1.09-2.92] 0.020
HLA matched 10/10 vs. ≤ 9/10 0.70 [0.50-0.97] 0.031
Patient age < 40 vs. > 40 0.58 [0.42-0.81] 0.001
p001/p001 vs. other Patient p001/p001 vs. other 1.73 [1.06-2.83] 0.030
genotypes HLA matched 10/10 vs. ≤ 9/10 0.70 [0.50-0.97] 0.032
(n=493) Patient age < 40 vs. > 40 0.58 [0.42-0.81] 0.001
1Factors are compared to the last one listed for their hazard ratio (HR). NRM: non-relapse mortality; OS: overall survival.
Figure 3. Survival analysis according to the
effects of patient and donor TGFB1 regula-
tory region and exon 1 genotype on non-
relapse mortality (NRM) for the whole
cohort. Allele p001 and -1347T homozygos-
ity in patients showed a significant
increase in NRM in the whole cohort. No
effect on NRM was observed for the donor
p001 dominant model. (A) Recessive
patient allelic model [(p001/p001 (n=41)
versus p003/p003 (n=132) versus het-
erozygous (n=309); overall P=0.099)]; (B)
patient p001/p001 (n=41) versus other
(n=452; P=0.039); (C) dominant patient -
1347C (-1347 TT (n=43) versus CT+CC
(n=450); P=0.029); (D) dominant donor
p001 (p001/- (n=246) versus other
(n=249); P=0.440). 
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another cause of death in which TGF-β1 might play a role,
such as impaired early immune responses to infectious
agents,19 organ damage,20 or complications such as hepatic
veno-occlusive disease.21 However, this remains unclear.
Interestingly, a recent report22 has shown evidence of a
role for TGF-β1 in limiting both the growth and function
of the thymic medulla, another potential niche for its
influence on the outcome of HSCT. 
Our typing results revealed that four TGFB1 regulatory
region and exon 1 alleles predominated. Even though this
was not a population study, our results provide insight
into TGFB1 regulatory region allelic diversity and frequen-
cies and are a potential reference for future studies.
Overall, the frequencies for variant polymorphic positions
and for TGFB1 regulatory region and exon 1 alleles agree
widely with data previously reported by other studies.23
We speculated that the strong detrimental effect of
patient p001 observed in this study was related to differ-
ences in functionality between TGFB1 regulatory region
and exon 1 alleles. Our study showed that the level of sur-
face TGF-β1 on Treg after TCR stimulation appears to be
modified by the presence of the p001 allele in TGFB1.
Even though it did not reach statistical significance,
TGFB1 p001/x genotypes showed results that suggested
higher generation of LAP+ cells when compared to TT
individuals, following previous observations in other cell
types and experimental systems.
The -1347T variant has been previously associated with
higher TGF-β1 plasma levels,24 as well as with a significant
increase in in vitro TGF-β1 expression25 via alteration of pro-
moter interactions with transcription factors Yin Yang 126
and AP1.27 Combining both the observations made for
TGFB1 -1347C>T and those made for +29T>C,28 Shah et
al. proposed that TGFB1 alleles that share a -1347T and
+29C would represent a high production phenotype.4
Allele p001 would be the sole representative of this cluster
seen with significant frequencies in our cohort.
Interestingly, a couple of studies have found opposite
results and associated -1347T and +29C with lower plas-
ma concentrations of this cytokine and lower reporter
gene activities,29 and a TGFB1 upstream haplotype congru-
ent with allele p001 with weaker promoter activity than
another haplotype fitting with allele p003.30 However, the
genomic region examined in the latter study only partially
spanned the one studied here and included different SNPs
not characterized in this study. Finally, one study associat-
ed allelic variants carrying a proline either in codon 10
(+29C) or 25 (+74C) with reduced expression, but only
included TGFB1 coding region in in vitro constructs.31
In addition to a -1347T variant, a feature that is unique
to p001 is the absence of the -2389AGG duplication
(rs11466313), and this has been associated with the gain of
allele DNA-protein complexes, potentially leading to
novel transcription factor binding site motifs.30 
Low frequency of homozygotes for some of the TGFB1
alleles precluded thorough analysis of their effects. A much
larger study would be needed for it to be possible to assess
homozygous individuals. In addition, since our cohort was
comprised mainly of alemtuzumab-T-cell- depleted trans-
plants, changes in its dosage or dosage schedule could have
taken place over the 13-year observation period, potentially
having an impact on our results. Unfortunately, this infor-
mation is not available for assessment. Finally, we do not
have data on replication of these results in an independent
cohort. Hence, these analyses should be confirmed in other
settings, such as non-myeloablative transplants or trans-
plants performed with alternative donors.
In conclusion, the fact that patients having a p001/p001
genotype have significantly higher probabilities of dying
early after the transplant could potentially allow for better
pre-emptive measures to improve the prognosis for these
patients. However, further research is needed to under-
stand the mechanism of this effect and the cause(s) of
death associated with it. 
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Figure 4. Surface TGF-β1 (LAP) expression on Treg upon TCR stimu-
lation differs according to TGFB1 regulatory region and exon 1 geno-
type in healthy donors. (A) Percentage of LAP+ cells between different
TGFB1 regulatory region and exon 1 genotypes. (B) The percentage of
LAP+ cells within the CD4+CD25+CD127lo gate shows a trend toward
higher expression when a p001 allele at TGFB1 regulatory region is
present. p001/other: p001/p001 (2), p001/p014 (2), p001/new (1).
Shown are mean and standard error. 
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